These 8 subjects are the last ones. After them, phase II is over.
Quote:
We have now completed the treatment phase of our Phase II study, being conducted by Dr Bessam Farjo in Manchester, to optimise the delivery of the DP cells.
…
We do not intend to finance the continuation of clinical and commercial development of ICX-TRC beyond the current Phase II trial and shall seek to sign a partner…
<<
As you can see, they are not going to continue research, and they are not going to commercialize it. Unless they get money from someone else. This means that the current investors are not interested on giving them more money for TRC.
Again… if the prestimulation technique is so good, why don’t they continue the PhaseII trials to fine-tune it, and increase the value of TRC, and then, start a small scale commercialization, like they are doing with Vavelta??
Continuing Phase II is not so expensive. Cohorts are very small.
» …“In the second sub-group, all patients showed
» substantial and visible increased hair counts at six or twelve weeks.
» A further eight subjects will be treated with variations in delivery
» technique. The full data set on all subjects at 24 weeks will be available
» in during 2008”
ICX is not giving us the real figures of these patients. In the last report, they gave obscure percentages. Now they are not giving us ANYTHING.
Common sense says to me: THIS IS OVER.
Unless Paul Kemp comes forward to us, and explains the whole thing, I would consider this OVER.
After so many years waiting, … we are back to the starting point.
It seems that we are cursed.
»
»
»
»
»
» Spanish Dude…if it is a bust, then they are outright
» lying to all of us. If thats the case…I’d put them in the
» boat Ive put Aderans in within my own thoughts-----which is to say I expect
» nothing out of them period. Aderans hasn’t even updated their website in
» almost two years, I can tell they are stuck. No trials, no trial
» data…stuck.
»
»
»
»
» Its either one or two things…either they think its sellable
» now, or they are stuck with haphazard results and arent willing to invest
» more time/money. In which case Follica is the only thing left with a
» chance.
No, they don’t think it is sellable, because they have said they don’t seek commercial development:
quote:
We do not intend to finance the continuation of clinical and commercial development of ICX-TRC beyond the current Phase II trial and shall seek to sign a partner…
<<<
Also, note that they are not mentioning 2010 as release date anymore in their website.